Vanguard Fiduciary Trust
TERN

Vanguard Fiduciary Trust’s Terns Pharmaceuticals TERN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-573,997
Closed -$30.3M – 4149
2026
Q1 		$30.3M Buy
+573,997
New +$23.6M 0.01% 1068

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Fiduciary Trust's TERN Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 573,997 shares — an estimated $30.3M sold.

Vanguard Fiduciary Trust first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $30.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Vanguard Fiduciary Trust reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Fiduciary Trust sold 573,997 Terns Pharmaceuticals shares in Q2 2026, an estimated $30.3M.
  • Vanguard Fiduciary Trust first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Fiduciary Trust's Terns Pharmaceuticals position peaked at $30.3M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.